[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Raivio et al., 2008 - Google Patents

Monitoring high-dose heparinization during cardiopulmonary bypass–A comparison between prothrombinase-induced clotting time (PiCT) and two chromogenic anti …

Raivio et al., 2008

Document ID
7184771175205735141
Author
Raivio P
Kuitunen A
Petäjä J
Ilveskero S
Lassila R
Publication year
Publication venue
Thrombosis and haemostasis

External Links

Snippet

Heparinization requires monitoring, but optimal methods for measuring the anticoagulant effects of heparin remain to be determined. We compared prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity (anti-Xa) assays in monitoring high …
Continue reading at www.thieme-connect.com (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G01N2800/226—Thrombotic disorders, i.e. thrombo-embolism irrespective of location/organ involved, e.g. renal vein thrombosis, venous thrombosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G01N33/4905—Determining clotting time of blood
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/811—Serine protease (E.C. 3.4.21) inhibitors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans

Similar Documents

Publication Publication Date Title
Despotis et al. Anticoagulation monitoring during cardiac surgery: a review of current and emerging techniques
Blome et al. Relationship between factor XIII activity, fibrinogen, haemostasis screening tests and postoperative bleeding in cardiopulmonary bypass surgery
Despotis et al. Antithrombin III during cardiac surgery: effect on response of activated clotting time to heparin and relationship to markers of hemostatic activation
US6566140B2 (en) Inhibition of coagulation in blood and blood products
Kumada et al. Comparative study on heparin and a synthetic thrombin inhibitor No. 805 (MD-805) in experimental antithrombin III-deficient animals
Gibbs et al. Postoperative changes in coagulant and anticoagulant factors following abdominal aortic surgery
Abuelkasem et al. Reduced requirement for prothrombin complex concentrate for the restoration of thrombin generation in plasma from liver transplant recipients
Schols et al. Impaired thrombin generation and fibrin clot formation in patients with dilutional coagulopathy during major surgery
Bagge et al. Coagulation, fibrinolysis and bleeding after open-heart surgery
Fang et al. Hemostatic management of extracorporeal circuits including cardiopulmonary bypass and extracorporeal membrane oxygenation
Ichikawa et al. Association between platelet count and postoperative blood loss in patients undergoing cardiac surgery with cardiopulmonary bypass and fresh frozen plasma administration guided by thromboelastometry
Gruenwald et al. Management and monitoring of anticoagulation for children undergoing cardiopulmonary bypass in cardiac surgery
Lax et al. Heparin dose and point-of-care measurements of hemostasis in cardiac surgery—results of a randomized controlled trial
Kanji et al. Optimal tests to minimise bleeding and ischaemic complications in patients on extracorporeal membrane oxygenation
He et al. The clotting trigger is an important determinant for the coagulation pathway in vivo or in vitro—inference from data review
Raivio et al. Monitoring high-dose heparinization during cardiopulmonary bypass–A comparison between prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity assays
Taketomi et al. Thrombin-activated thrombelastography for evaluation of thrombin interaction with thrombin inhibitors
Rumph et al. In vitro comparative study of hemostatic components in warfarin-treated and fibrinogen-deficient plasma
Despotis et al. Pathophysiology, prevention, and treatment of bleeding after cardiac surgery: a primer for cardiologists and an update for the cardiothoracic team
Bolliger et al. Factor concentrate-based approaches to blood conservation in cardiac surgery: European perspectives in 2020
Rossi et al. The role of antithrombin III in the perioperative management of the patient with unstable angina
Tapper et al. Evaluation of hemostatic factors in patients undergoing major hepatic resection and other major abdominal surgeries
Hellstern Composition of plasma
McMillan et al. Coagulation disorders in congenital heart disease
Despotis et al. Heparin resistance and the potential impact on maintenance of therapeutic coagulation